Quotables
"Inventing is a combination of brains and materials. The more brains you use, the less material you need."
Charles Kettering
PatentStorm News
Make the Most of PatentStorm
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest patents by subscribing to an RSS feed.
Got questions? Ask a Patent Expert!
Registered users: Manage your profile, comments and alerts.
US Patent 5464854 - Method of modifying ovarian hormone-regulated AT1 receptor activity as treatment of incapacitating symptom(s) of P.M.S.
US Patent Issued on November 7, 1995
Estimated Patent Expiration Date:
April 29, 2014Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
Estimated Patent Expiration Date:
April 29, 2014Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.AbstractThe method of treatment moderating, blocking and/or eliminating premenstrual syndrome embodies the intermittent administering of an AT1 antagonist to a female having menstrual cycles characterized predominately by during substantially the luteal phase inclusive of at least one and frequently by two or more affective and/or autonomic and/or somatic symptoms of substantially incapacitating severity(ies) proximately substantially prior to menses of a menstrual cycle. Losartan is an example of an AT1 inhibitor and is administered either orally or parenterally continuously to a female during her menstrual cycle's luteal phase.Other References
| InventorApplicationNo. 235468 filed on 04/29/1994US Classes:514/381, Tetrazoles (including hydrogenated)514/223.5, With additional active ingredient514/303, Exactly three ring nitrogens in the bicyclo ring system514/394, Benzo fused at 4,5-positions of the diazole ring514/397, Additional hetero ring514/417Plural chalcogens bonded directly to ring carbons of the five-membered hetero ring (e.g., phthalimide, etc.)Field of Search514/303, Exactly three ring nitrogens in the bicyclo ring system514/381, Tetrazoles (including hydrogenated)514/394, Benzo fused at 4,5-positions of the diazole ring514/397, Additional hetero ring514/223.5, With additional active ingredient514/417Plural chalcogens bonded directly to ring carbons of the five-membered hetero ring (e.g., phthalimide, etc.)ExaminersPrimary: Jordan, KimberlyAttorney, Agent or FirmUS Patent References4912096, Method for preventing or treating depression employing an ace inhibitorIssued on: 03/27/1990 Inventor: Sudilovsky4931430, Method for preventing or treating anxiety employing an ACE inhibitor Issued on: 06/05/1990 Inventor: Sudilovsky, et al.5246943Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties Issued on: 09/21/1993 Inventor: Blankley, et al. International ClassesA61K 031/54A61K 031/44 A61K 031/41 A61K 031/415 A61K 031/40 |
